Showing results (61-70 of 69) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Breast (Edinburgh, Scotland)|January 8, 2014
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)N McCarthy, F Boyle, N Zdenkowski, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study GroupG Marini, S Murray, A Goldhirsch, et al.British Journal of Cancer|November 17, 2004
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancerJ Bernhard, D Zahrieh, A S Coates, et al.Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.Oncogene|September 25, 1998
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalR Hui, J R Ball, R D Macmillan, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.Pageof 7